Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

Ms_P Aug. 31 at 12:45 PM

$VRNA any respiratory experts following $GOSS? They have a phase 3 readout next February. A few upcoming conferences to learn more: https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-present-upcoming-investor-conferences/

0 · Reply

MOOSEN Aug. 29 at 9:08 PM

$GOSS YE.

0 · Reply

StockScubaDiver Aug. 29 at 7:39 PM

$GOSS

0 · Reply

BillyBobBleach Aug. 29 at 4:18 PM

$GOSS https://www.businesswire.com/news/home/20250829692001/en/Gossamer-Bio-to-Present-at-Upcoming-Investor-Conferences

0 · Reply

Fisherman10 Aug. 29 at 12:59 PM

$GOSS So it begins speaking at investors conference. The slow ascent will continue. $10 closer than you think. Approval = $20.

2 · Reply

Gunhead01 Aug. 29 at 8:14 AM

$GOSS

0 · Reply

StockBoiChris Aug. 29 at 2:56 AM

$GOSS hopefully man, I’ve pretty much given up

1 · Reply

boomupwego Aug. 28 at 9:26 PM

$GOSS To those curious as to why more funds haven’t gotten on the wagon yet with all the promising outlooks, it’s very simple: they can’t. A lot of funds that handle other people’s money (think 401k) have rules in place that don’t allow penny stock (under $5) purchases because of the inherent volatility. Be patient, hold, and reap the eventual rewards.

0 · Reply

boomupwego Aug. 28 at 5:53 PM

$GOSS Once RSI balances out, feel this is gonna run. It’s a win-win for MM’s. Buy up cheap shares now if/when P3 comes back positive. If P3 fails, they’ll leverage out the shares through shorts and still make millions.

1 · Reply

MOOSEN Aug. 28 at 3:40 PM

$SLS GOT DEM $GOSS SCALPS ROLLING IN.

0 · Reply

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 7, 2025, 5:30 PM EDT - 23 days ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 5, 2025, 4:01 PM EDT - 25 days ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 16, 2025, 7:31 AM EDT - 2 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

May 15, 2025, 9:30 PM EDT - 3 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:01 PM EDT - 3 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 12, 2025, 4:01 PM EDT - 3 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 7, 2025, 4:01 PM EDT - 4 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Mar 13, 2025, 4:01 PM EDT - 6 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 7:42 PM EST - 7 months ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 3, 2025, 7:01 AM EST - 7 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 7 months ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Nov 7, 2024, 4:03 PM EST - 10 months ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Dec 13, 2023, 4:01 PM EST - 1 year ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 5, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Nov 29, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 9, 2023, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Mar 17, 2023, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Jan 30, 2023, 4:48 AM EST - 2 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Dec 8, 2022, 1:27 PM EST - 2 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 6, 2022, 8:19 AM EST - 2 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 7:15 AM EST - 2 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Nov 3, 2022, 4:01 PM EDT - 3 years ago

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

Oct 20, 2022, 3:35 PM EDT - 3 years ago

This little-known biopharma stock could rally 70%: Goldman Sachs

Aug 9, 2022, 8:01 AM EDT - 3 years ago

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

Jul 13, 2022, 7:15 AM EDT - 3 years ago

Gossamer Bio Announces $120 Million Private Placement Financing

Jun 9, 2022, 8:30 AM EDT - 3 years ago

Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAH

May 10, 2022, 4:01 PM EDT - 3 years ago

Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

Ms_P Aug. 31 at 12:45 PM

0 · Reply

MOOSEN Aug. 29 at 9:08 PM

$GOSS YE.

0 · Reply

StockScubaDiver Aug. 29 at 7:39 PM

$GOSS

0 · Reply

BillyBobBleach Aug. 29 at 4:18 PM

$GOSS https://www.businesswire.com/news/home/20250829692001/en/Gossamer-Bio-to-Present-at-Upcoming-Investor-Conferences

0 · Reply

Fisherman10 Aug. 29 at 12:59 PM

$GOSS So it begins speaking at investors conference. The slow ascent will continue. $10 closer than you think. Approval = $20.

2 · Reply

Gunhead01 Aug. 29 at 8:14 AM

$GOSS

0 · Reply

StockBoiChris Aug. 29 at 2:56 AM

$GOSS hopefully man, I’ve pretty much given up

1 · Reply

boomupwego Aug. 28 at 9:26 PM

0 · Reply

boomupwego Aug. 28 at 5:53 PM

1 · Reply

MOOSEN Aug. 28 at 3:40 PM

$SLS GOT DEM $GOSS SCALPS ROLLING IN.

0 · Reply

Hereinbama35 Aug. 28 at 3:31 PM

$GOSS Guys I’m so sorry. I don’t know where my super power comes from but every fricking fracking time I buy more of this it dives an hour later! 😡

1 · Reply

tothemoonalice24 Aug. 28 at 1:55 PM

Hate to say it but this is going down. No catylast between now and February read out. Would love to see some insider buys but how much longer can they buy before clinical read out to begin with? $GOSS

2 · Reply

King_of_Bio Aug. 28 at 1:45 PM

$CMPX $GOSS $TSHA $AKBA Bio stocks you rarely ever hear about that are doing VERY well and will make shareholders VERY wealthy in years to come. If you know, you know. Good luck all - it's ALWAYS bio season.

2 · Reply

Hereinbama35 Aug. 27 at 4:48 PM

$GOSS No that would be me.

0 · Reply

StockBoiChris Aug. 27 at 4:37 PM

$GOSS yes 👏

0 · Reply

joaneegell Aug. 27 at 4:30 PM

$GOSS sorry y'all, I bought some so it went down, of course.

0 · Reply

Crawford20120 Aug. 27 at 4:22 PM

$GOSS Healthy drop, RSI was too high...its doing its own cycle. $10 is the goal. 6 months to go. Keep accumulating and keep your eyes on Feb 2026.

0 · Reply

wallstpirate Aug. 27 at 2:43 PM

$GOSS Who thinks this is good news a dinner to discuss P3 . GOSS In-Person NYC Dinner on Sep. 3rd at 6:00 PM ET. Join us on September 3rd at 6:00 PM ET in NYC for a dinner with GOSS mgmt as we head into highly anticipated Ph3 PROSERA PAH topline data guided for February 2026 PIPER

0 · Reply

MOOSEN Aug. 27 at 1:53 PM

$GOSS

0 · Reply

StockBoiChris Aug. 27 at 8:22 AM

$GOSS 2.70 or sub 2.40; there will be no in between …🤷‍♂️

0 · Reply

ForexFighter Aug. 27 at 6:46 AM

$GOSS consolidating in a tight range, could be setting up for a bigger move.

0 · Reply

mdalinaqvi Aug. 27 at 5:09 AM

$GOSS Next resistance as per woodies pivot points is $2.57, beyond that 🚀 Classical pivot is at $3.20 🚀

0 · Reply

Market Cap	561.63M
Revenue (ttm)	114.70M
Net Income (ttm)	-56.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-49.29%
Debt to Equity Ratio	0.00

Volume	2,537,600
Avg Vol	3,200,766
Day's Range	N/A - N/A
Shares Out	227.38M
Stochastic %K	77%
Beta	1.96
Analysts	Strong Sell
Price Target	$8.16